Research programme: retinal disorder therapeutics - Kodiak Sciences

Drug Profile

Research programme: retinal disorder therapeutics - Kodiak Sciences

Alternative Names: KSI 201; KSI 301; KSI 401; KSI-501

Latest Information Update: 02 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oligasis
  • Developer Kodiak Sciences
  • Class Eye disorder therapies; Immunoconjugates
  • Mechanism of Action Angiogenesis inhibitors; Angiotensinogen modulators; Complement system protein inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic retinopathy; Dry age-related macular degeneration; Wet age-related macular degeneration

Most Recent Events

  • 26 Apr 2018 Preclinical trials in Diabetic retinopathy, Dry age-related macular degeneration, and Wet age-related macular degeneration in USA (Parenteral), prior to April 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top